Lineage Cell Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals of $716.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $716.00K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals $0.00.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals |
|---|---|
| 2025-12-31 | $716.00K 10-K · filed 2026-03-05 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |